Changes in Human Gut Microbiome in Healthy Adults
Conditions
Keywords
Thymoquinone, Gut microbiome, Nigella sativa seed oil, Microbiota modulation, Thymoquionone metabolism
Brief summary
For many patients, the additive use of dietary supplements without side effects is motivating for therapy and enhances quality of life. The oil of the plant Nigella sativa (NS), a dietary supplement containing Thymoquinone (TQ) as its main active compound, exhibits hepatoprotective effects through antioxidative, antifibrotic, and anti-inflammatory properties, and also demonstrates anticancer and antiapoptotic activities. In vitro and in vivo studies have shown that TQ can also influence the gut microbiome. However, no clinical studies are currently available that describe the specific extent of TQ's influence on the human intestinal microbiome and its potential effects on the outcome after gastrointestinal surgery. The aim of the project is therefore to investigate changes in the human microbiome following the intake of Nigella sativa seed oil capsules containing TQ as the main active ingredient. The study will test the hypothesis that TQ, through its diverse mechanisms of action, modulates the composition of the microbiome and thereby exerts a positive effect on immune response and intestinal healing processes. In parallel, TQ metabolites in urine will be analyzed using Liquid Chromatography-Mass Spectrometry (LC-MS) to gain insights into the pharmacokinetic profile of the compound.
Interventions
Intake of two Thymoquinone (TQ) containing Nigella Sativa Seed Oil (NSSO) capsules three times daily for 20 days and provision of fecal samples at five time points.
Sponsors
Study design
Eligibility
Inclusion criteria
* no recent medication use * no history of gastrointestinal surgery * no pregnancy * no allergies to NSSO or its derivatives * healthy * 18 years and above
Exclusion criteria
* regular medication * history of gastrointestinal surgery * pregnancy * allergies to NSSO or its derivates * presence of chronic illness * below the age of 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in bacterial taxa in fecal samples | From enrollment to the end of treatment at 20 days. |
Countries
Germany